Since the FDA announced that tirzepatide is (for now) out of shortage, APC’s Scott Brunner has been...
CNN’s Meg Tirrell gets to the heart of the matter in “The end of a shortage of popular weight-loss drugs may mean many people lose access to them.” She focuses on patients who have come to rely on compounded tirzepatide and how they might be priced out of Lilly’s brand-name versions.
Bonus: The article quotes both CEO Scott Brunner and board member Jennifer Burch.
Since the FDA announced that tirzepatide is (for now) out of shortage, APC’s Scott Brunner has been...
The Washington Post’s story “Eli Lilly ramps up its fight against imitation weight-loss drugs”...
NPR ran an updated story on the ‘battle’ between compounders and drug makers over GLP-1 weight-loss...